Zacks Small Cap Analysis – ARWR: PALISADE Part 3 Outcomes Revealed in NEJM… – Go Well being Professional
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more
